TipRanks
Santhera Pharmaceuticals Holding (SPHDF)
OTHER OTC:SPHDF
US Market
SPHDF
Santhera Pharmaceuticals Holding
RESEARCH TOOLSreports

Santhera Pharmaceuticals Holding (SPHDF) Stock News & Sentiment

40 Followers
Santhera Pharmaceuticals’ Earnings Call Signals Robust Growth
Premium
Company Announcements
Santhera Pharmaceuticals’ Earnings Call Signals Robust Growth
1d ago
Santhera: Buy Rating Reiterated as AGAMREE Traction and Governance Stability Support Unchanged CHF30 Price Target
Premium
Ratings
Santhera: Buy Rating Reiterated as AGAMREE Traction and Governance Stability Support Unchanged CHF30 Price Target
4M ago
Analyst Reiterates Buy on Santhera, Citing Leadership Transition and AGAMREE Momentum with Unchanged $30 Price Target
Premium
Ratings
Analyst Reiterates Buy on Santhera, Citing Leadership Transition and AGAMREE Momentum with Unchanged $30 Price Target
5M ago
Santhera: Advancing AGAMREE Reimbursement and European Uptake Underpins Reiterated Buy and CHF30 Target
Premium
Ratings
Santhera: Advancing AGAMREE Reimbursement and European Uptake Underpins Reiterated Buy and CHF30 Target
6M ago
Santhera Pharmaceuticals Advances Vamorolone Study for Duchenne Muscular Dystrophy
Premium
Company Announcements
Santhera Pharmaceuticals Advances Vamorolone Study for Duchenne Muscular Dystrophy
11M ago
SPHDF
Santhera’s Earnings Call: Positive Outlook Amid Challenges
Premium
Company Announcements
Santhera’s Earnings Call: Positive Outlook Amid Challenges
12M ago
Santhera Pharmaceuticals Reports Strong H1 2025 Growth
Premium
Company Announcements
Santhera Pharmaceuticals Reports Strong H1 2025 Growth
1y ago
More SPHDF News >

SPHDF News on the Web

Santhera: Advancing AGAMREE Reimbursement and European Uptake Underpins Reiterated Buy and CHF30 Target
TipRanks News
Bullish
Santhera Pharma Appoints Marc Clausse As Chief Commercial Officer
rttnews
Bullish
Swissmedic Approves Santhera's AGAMREE For Duchenne Muscular Dystrophy
rttnews
Bullish
Santhera Pharmaceuticals Reports Strong H1 2025 Growth
TipRanks News
Neutral
Week In Review: AriBio Sells China Rights To Alzheimer’s Candidate In $770 Million Deal
TalkMarkets
Neutral
Analysts Offer Insights on Healthcare Companies: Santhera Pharmaceuticals Holding (OtherSPHDF), Ironwood Pharma (IRWD) and Cytokinetics (CYTK)
TipRanks News
Neutral
3 Unstoppable S&P 600 Small-Cap Stocks to Buy in January
InvestorPlace
Neutral
Analysts Conflicted on These Healthcare Names: Amylyx Pharmaceuticals Inc (AMLX), Santhera Pharmaceuticals Holding (OtherSPHDD) and Alkermes (ALKS)
TipRanks News
Neutral

News Score - Last 7 Days

Positive
SPHDF
Sector Average
Media Buzz
This Week3 articles
Weekly Average0 articles
News Sentiment
This Week100%
Sector Average91%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is SPHDF’s Media Buzz Sentiment?
Currently, no data Available
What is SPHDF’s weekly average amount of articles?
Currently, no data Available
What is SPHDF’s News Sentiment?
100% of articles about SPHDF were positive this week, compared to its sector average of 91%.
    Healthcare Stocks that are Trending in the News
    SYRESpyre Therapeutics
    BAYRYBayer
    QTTBQ32 Bio
    CICigna
    ZYMEZymeworks
    Showing the stocks with the most bullish news sentiment over the past week